Please assess the completion status of the following clinical trial:

Trial Title: Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically confirmed diagnosis of metastatic (Stage IV) breast cancer;~* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST);~* Triple negative disease defined as tumor demonstrating no expression for estrogen, progesterone or HER2 receptors. (No expression is categorized as ≤ 10% of cells staining or Allred ≤ 2);~* Aged 18 years or older;~* Eastern Cooperative Oncology Group (ECOG)ECOG/Zubrod performance status of 0 or 1; life expectancy ≥ 3 months;~* No prior chemotherapy for metastatic disease.~* At least 6 months must have elapsed since prior adjuvant chemotherapy.~* Laboratory tests performed within 14 days of study entry showing:~  * Granulocytes ≥ 1,500/µL;~ * Platelets ≥ 100,000/µL;~ * Hemoglobin ≥ 9.0 gm/dL;~ * Total bilirubin ≤ institutional upper limit of normal (ULN);~ * Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN;~ * Alkaline phosphatase ≤ 5 times ULN;~ * Estimated creatinine clearance ≥ 60 mL/min.~ * Urine protein:creatinine ratio ≤ 1.0. or 24 hour urine protein collection demonstrating ≤ 1 gram of protein per 24 hours to be eligible.~* left ventricular ejection fraction (LVEF) ≥ 50% by multiple gated acquisition scan (MUGA)/Echocardiogram;~* Informed consent to receive protocol treatment:~* Cognitive and communication skills adequate to comply with study and/or follow-up procedures;~* Geographic proximity and ability to comply with weekly study visits for the duration of the treatment;~* No reproductive potential:~  * If pre-menopausal - Negative serum pregnancy test within 3 days prior to initiation of protocol-based treatment and patient agrees to use contraceptive method (abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during and for 3 months after completion of protocol treatment;~ * If post-menopausal - Amenorrhea for ≥ 12 months or follicle stimulating hormone (FSH) within post menopausal range.~Exclusion Criteria:~* Pregnant or breast feeding.~* Prior treatment with Abraxane® or carboplatin.~* Prior chemotherapy for metastatic breast cancer.~* Known hypersensitivity to any component of any study drug.~* Active infection.~* Current neuropathy ≥ grade 2.~* central nervous system (CNS) metastases as determined by head CT with contrast or head MRI.~* Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months.~* Uncontrolled serious contraindicated medical condition or illness.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abraxane, Carboplatin (Type: EXPERIMENTAL): Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).